The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Ca

The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer is a phase 3, randomised interventional study registered as NCT05984485 by Sun Yat-sen University, with a registry enrolment figure of 766 participants, started 2022-07-05 and due to reach its primary completion in 2028-07. Interventions recorded: neoadjuvant chemotherapy plus total mesorectal excision; total mesorectal excision. Conditions listed: Rectal Cancer. Primary outcome: 3-year Disease Free Survival. Colorectal eligibility wording from the registry: "Pathologically confirmed rectal adenocarcinoma;". Sites: China. No results are recorded here; the registry entry is the source.